Skip to content

Safety of dexamethasone suppression test for adrenal masses

Safety of dexamethasone suppression test for adrenal masses

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
JPRN
Registry ID
JPRN-jRCT1021230051
Enrollment
40
Registered
2024-01-12
Start date
2024-01-12
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

adrenal mass adrenal mass

Interventions

None listed

Sponsors

Murasawa Shingo
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Patients admitted to our hospital for the examination of adrenal masses and need to rule out cortisol excess production

Exclusion criteria

Exclusion criteria: Patients on oral steroid therapy.

Design outcomes

Primary

MeasureTime frame
After drawing blood at rest at 23:00 midnight, patients take 1 to 2 dexamethasone 0.5 mg tablets. Fasting resting blood samples will be taken at 6-7 a.m. the next morning, and blood pressure on the morning of dexamethasone administration will be compared with that on the morning of the next day. In addition to adrenocorticotropic hormone and cortisol as originally evaluated in the 1 mg dexamethasone study, blood counts and biochemical tests (blood catecholamine, AST, ALT, ALP, gamma GTP, NT-proBNP, CPK, BUN, Cre, Na, K, Cl) will be taken.

Contacts

Public ContactShingo Murasawa

Hirosaki University Graduate School of Medicine

murashin@hirosaki-u.ac.jp+81-172-39-5062

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026